Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

L Rochette, C Guenancia, A Gudjoncik… - Trends in …, 2015 - cell.com
Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction
resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines …

The HSP90 molecular chaperone—an enigmatic ATPase

LH Pearl - Biopolymers, 2016 - Wiley Online Library
The HSP90 molecular chaperone is involved in the activation and cellular stabilization of a
range of 'client'proteins, of which oncogenic protein kinases and nuclear steroid hormone …

Hsp90 mediates membrane deformation and exosome release

E Lauwers, YC Wang, R Gallardo, R Van der Kant… - Molecular cell, 2018 - cell.com
Hsp90 is an essential chaperone that guards proteome integrity and amounts to 2% of
cellular protein. We now find that Hsp90 also has the ability to directly interact with and …

Targeting mutant p53 for cancer treatment: moving closer to clinical use?

MJ Duffy, M Tang, S Rajaram, S O'Grady, J Crown - Cancers, 2022 - mdpi.com
Simple Summary Cancer is largely caused by genetic alterations such as mutations in a
group of genes known as cancer driver genes. Many of the key advances in cancer …

Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside

M Aruanno, E Glampedakis… - Antimicrobial agents and …, 2019 - Am Soc Microbiol
ABSTRACT Echinocandins (caspofungin, micafungin, anidulafungin), targeting β-1, 3-
glucan synthesis of the cell wall, represent one of the three currently available antifungal …

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

RM Mbofung, JA McKenzie, S Malu, M Zhang… - Nature …, 2017 - nature.com
T-cell-based immunotherapies are promising treatments for cancer patients. Although
durable responses can be achieved in some patients, many patients fail to respond to these …

[HTML][HTML] Combination therapies with HSP90 inhibitors against colorectal cancer

K Kryeziu, J Bruun, TK Guren, A Sveen… - Biochimica et Biophysica …, 2019 - Elsevier
Oncogene stability and homeostasis mediated by the HSP90 chaperone is a crucial
protection trait of cancer cells. Therefore, HSP90 represents an attractive therapeutic target …

First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma

VC Gibouin, M Durand, C Boudesco, F Hermetet… - Leukemia, 2024 - nature.com
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant
activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat …

Biological actions of the Hsp90-binding immunophilins FKBP51 and FKBP52

NR Zgajnar, SA De Leo, CM Lotufo, AG Erlejman… - Biomolecules, 2019 - mdpi.com
Immunophilins are a family of proteins whose signature domain is the peptidylprolyl-
isomerase domain. High molecular weight immunophilins are characterized by the …

Adapting to stress—chaperome networks in cancer

S Joshi, T Wang, TLS Araujo, S Sharma… - Nature Reviews …, 2018 - nature.com
In this Opinion article, we aim to address how cells adapt to stress and the repercussions
chronic stress has on cellular function. We consider acute and chronic stress-induced …